Floatz logo

tt125-802

KRAS G12C

TOLREMO therapeutics AGPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
Adagrasib
Ryan Gentzler, MD
Phase 2CCC
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Opnurasib
Maastricht University Medical Center
Phase 2CCC
Fulzerasib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2CCC

View all 23 →

Same molecule, other indications

tt125-802 is also rated in:

Adult DiseaseDormant
CC
Indicative ·
47 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Adult Solid TumorDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →